Cerus Corporation  

(Public, NASDAQ:CERS)   Watch this stock  
Find more results for CERS
6.75
+0.15 (2.27%)
After Hours: 6.75 0.00 (0.00%)
Aug 26, 6:52PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.47 - 6.85
52 week 4.27 - 7.64
Open 6.56
Vol / Avg. 1.67M/1.32M
Mkt cap 694.34M
P/E     -
Div/yield     -
EPS -0.66
Shares 102.71M
Beta 1.91
Inst. own 71%
Nov 3, 2016
Q3 2016 Cerus Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 8, 2016
Cerus Corp at Robert W Baird Global Healthcare Conference - 12:50PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Cerus Corp Earnings Call
Aug 4, 2016
Q2 2016 Cerus Corp Earnings Release
Jul 13, 2016
Cerus Corp at Cantor Fitzgerald Healthcare Conference
Jun 20, 2016
Cerus Corp Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -196.37% -163.25%
Operating margin -180.94% -178.46%
EBITD margin - -173.50%
Return on average assets -58.67% -50.52%
Return on average equity -92.13% -81.99%
Employees 176 -
CDP Score - -

Address

2550 Stanwell Dr
CONCORD, CA 94520-4813
United States - Map
+1-925-2886000 (Phone)
+1-925-2886001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Officers and directors

Daniel N. Swisher Jr. Independent Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
William M. Greenman President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Kevin D. Green Chief Financial Officer, Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Caspar Hogeboom President, Cerus Europe and EEMEA
Age: 56
Bio & Compensation  - Reuters
Laurence M. Corash M.D. Senior Vice President, Chief Medical and Chief Scientific Officer, Director
Age: 71
Bio & Compensation  - Reuters
Carol M. Moore Senior Vice President - Regulatory Affairs, Quality and Clinical
Age: 65
Bio & Compensation  - Reuters
Richard J. Benjamin Chief Medical Officer
Bio & Compensation  - Reuters
Chrystal N. Menard Chief Legal Officer and General Counsel
Age: 44
Bio & Compensation  - Reuters
Timothy Bruce Anderson Independent Director
Age: 68
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 52
Bio & Compensation  - Reuters